Latest News
Yesterday 10:06pm — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Crea...
Thursday November 27, 2008 — Zacks.com: Analyst Blog
Barr Pharmaceuticals, Inc. (BRL) is a global specialty pharmaceutical company engaged in the development, manufacture and marketing of branded and generic drugs. On July 18, 2008, Barr announced that it has entered into an agreement with Teva Pharmaceuticals (TEVA) whereby the latter will...
Thursday November 27, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 26 /PRNewswire/ -- Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix(R) (cyclobenzaprine hydrochloride) extended-release capsules, 15mg and 30mg.Barr ...
Saturday November 22, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. ."Today's vote demonstrated the overwhelming supp...
Saturday November 22, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. ."Today's vote demonstrated the overwhelming supp...
Saturday November 22, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. ."Today's vote demonstrated the overwhelming supp...
Wednesday November 19, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12...
Wednesday November 19, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12...
Wednesday November 19, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12...
Wednesday November 19, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R) AQ (triamcinolone acetonide) nasal spray, Allegra(R) D-12...
Thursday November 6, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today reported net earnings of $31 million, or $0.28 per share, on revenues of $737 million for the quarter ended September 30, 2008. The current quarter results compare with prior year net earnings of $39 million, or $0...
Tuesday November 4, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Camptosar(R) (irinotecan hydrochloride) Inj...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Tuesday October 28, 2008 — Barr Pharmaceuticals, Inc.
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured credit facilities to permit...
Monday October 27, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for LoSEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.10 ...
Saturday October 25, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Watson Laboratories, Inc. in connection with its Oxytrol(R) (oxybutynin transdermal system). The Company b...
Wednesday October 22, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release ...
Saturday October 18, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 17 Barr Pharmaceuticals, Inc. today announced that the Company has revised the time of its conference call to discuss earnings results for the third quarter of calendar 2008, ended September 30, 2008. The Company revised the time of its Conference Call to 9:00 AM Eastern time...